Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0YU5H
|
|||
Former ID |
DNC007805
|
|||
Drug Name |
6-(4-((benzylamino)methyl)phenoxy)nicotinamide
|
|||
Synonyms |
CHEMBL238316; 6-(4-((benzylamino)methyl)phenoxy)nicotinamide; SCHEMBL3700197; LUBVSQAMVPXMBJ-UHFFFAOYSA-N; BDBM50219916
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C20H19N3O2
|
|||
Canonical SMILES |
C1=CC=C(C=C1)CNCC2=CC=C(C=C2)OC3=NC=C(C=C3)C(=O)N
|
|||
InChI |
1S/C20H19N3O2/c21-20(24)17-8-11-19(23-14-17)25-18-9-6-16(7-10-18)13-22-12-15-4-2-1-3-5-15/h1-11,14,22H,12-13H2,(H2,21,24)
|
|||
InChIKey |
LUBVSQAMVPXMBJ-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Opioid receptor delta (OPRD1) | Target Info | Inhibitor | [1] |
Opioid receptor kappa (OPRK1) | Target Info | Inhibitor | [1] | |
Opioid receptor mu (MOP) | Target Info | Inhibitor | [1] | |
KEGG Pathway | Neuroactive ligand-receptor interaction | |||
cGMP-PKG signaling pathway | ||||
Sphingolipid signaling pathway | ||||
Estrogen signaling pathway | ||||
Morphine addiction | ||||
NetPath Pathway | TCR Signaling Pathway | |||
Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
Opioid prodynorphin pathway | ||||
Enkephalin release | ||||
Opioid proenkephalin pathway | ||||
Opioid proopiomelanocortin pathway | ||||
Pathway Interaction Database | IL4-mediated signaling events | |||
Reactome | Peptide ligand-binding receptors | |||
G alpha (i) signalling events | ||||
WikiPathways | GPCRs, Class A Rhodopsin-like | |||
Peptide GPCRs | ||||
GPCR ligand binding | ||||
GPCR downstream signaling | ||||
TCR Signaling Pathway | ||||
Opioid Signalling |
References | Top | |||
---|---|---|---|---|
REF 1 | Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5349-52. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.